SRSF12 is a prognostic biomarker involved in immune infiltration in acute myeloid leukemia
| Autor: | MengMeng Zhang, YuanYuan Tan, ZhiBin Xie, Meng Wang, JiaJia Li |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Hematology, Vol 29, Iss 1 (2024) |
| Druh dokumentu: | article |
| ISSN: | 16078454 1607-8454 |
| DOI: | 10.1080/16078454.2024.2420301 |
| Popis: | Background Acute myeloid leukemia (AML) is a disease characterized by the proliferation of abnormal cells originating from blood stem cells. Understanding the pathogenesis and progression of AML, as well as identifying molecular markers for early diagnosis and prognosis assessment, is of paramount importance.Methods The AML dataset was obtained from the Cancer Genome Atlas (TCGA), while the normal sample dataset was derived from the Genotype-Tissue Expression(GTEx) dataset. Furthermore, the association between SRSF12 expression and drug response was assessed using the Cancer Therapeutic Response Portal (CTRP) database to evaluate its potential therapeutic value. Finally, SRSF12 expression in AML cells was measured using quantitative real-time PCR (qRT-PCR).Result The difference in SRSF12 expression between 13 types of tumors and normal tissue samples was found to be statistically significant (P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|